Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2 / Phase 3interventionalRules rewrite

Phase 2 / Phase 3: testing EB-1020 (Centanafadine) 164.4 mg for Attention Deficit Hyperactivity Disorder (ADHD)

This study wants to measure the how well it works and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

Official registry: https://clinicaltrials.gov/study/NCT06931080 · Otsuka Pharmaceutical Co., Ltd. · enrollment listed as 630

What this phase means

Phase 2/3: earlier tests looked promising enough to expand. This stage asks, in a larger group, whether the treatment really works and is safe enough to seek approval.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, or Placebo. The registry lists allocation as randomized. This study wants to measure the how well it works and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

They plan to enroll about 630 people at Tokyo. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of EB-1020 Once Daily QD XR Capsules Administered Orally at Low or High Dose in Adults With Attention-deficit/Hyperactivity Disorder

Interventions: EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, Placebo

Primary outcome (registry wording): Change from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) score at Week6

Who it is for (from inclusion criteria)

  • Ages 18 Years to 55 Years
  • Participants with an AISRS total score meeting the following criteria:
  • Not receiving medication treatment for ADHD: 28 points or higher
  • Receiving medication treatment for ADHD: 22 points or higher

Public study contact (from the registry)

Drug Information Center

+81-3-6361-7314

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBoston, Massachusetts
National Pregnancy Registry for Psychiatric Medications

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

NCT01246765 · Official ClinicalTrials.gov record · Massachusetts General Hospital

RecruitingNot a traditional drug phaseSacramento, California
Not a traditional drug phase: VR Treatment for ADHD

Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents.

NCT03221244 · Official ClinicalTrials.gov record · University of California, Davis

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: testing The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: for Coronavirus Infection (COVID-19)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to measure the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

NCT04278404 · Official ClinicalTrials.gov record · Duke University

FAQ about this NCT record

Is NCT06931080 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06931080?

Phase 2 / Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06931080?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary